innovations
FyMed Heralds Breakthrough in the Treatment of Colon Cancer with Novel Drug Candidate FY405B
16/02/15 08:00
Scientists at FyMed, Inc. have identified a novel drug target in the management of colon cancer, developing a candidate that has shown significant promise for the treatment of this difficult-to-treat disease in early studies. Read More...
FY103B Identified to Exhibit Profound Antineoplastic Effects in the Digestive Tract
12/10/14 10:30
Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. Read More...
FyMed Announces Top-Line Results Demonstrating Superiority of FY103B over Celecoxib in the Treatment of Pain and Inflammation
22/04/14 11:10
FyMed, Inc. today announced top-line results from studies of FY103B, its new NSAID candidate, which demonstrated significant superiority over celecoxib in terms of efficacy and safety. Read More...
FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen In the Treatment of Pain and Inflammation
19/07/13 10:30
FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and safety in the management of acute and chronic pain and inflammation. Read More...